AIM
UTHR icon

Aigen Investment Management’s United Therapeutics UTHR Stock Holding History

Aigen Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-693
Closed -$411K – 805
2026
Q1 		$411K Buy
+693
New +$345K 0.11% 265
2025
Q4 		– Sell
-4,354
Closed -$1.83M – 999
2025
Q3 		$1.83M Buy
4,354
+434
+11% +$146K 0.28% 83
2025
Q2 		$1.13M Buy
+3,920
New +$1.17M 0.15% 213
2021
Q4 		– Sell
-1,378
Closed -$254K – 1190
2021
Q3 		$254K Buy
+1,378
New +$271K 0.05% 373
2020
Q2 		– Sell
-150
Closed -$14K – 1311
2020
Q1 		$14K Sell
150
-1,772
-92% -$168K ﹤0.01% 1127
2019
Q4 		$169K Buy
+1,922
New +$169K 0.03% 594

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Aigen Investment Management's UTHR Position: Q2 2026 in Review

Aigen Investment Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 693 shares — an estimated $411K sold.

Aigen Investment Management first reported a position in UTHR in Q4 2019 and held it in 6 quarters. The position peaked at $1.83M in Q3 2025. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Aigen Investment Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aigen Investment Management sold 693 United Therapeutics shares in Q2 2026, an estimated $411K.
  • Aigen Investment Management first reported a position in United Therapeutics in Q4 2019 and held it in 6 quarters.
  • Aigen Investment Management's United Therapeutics position peaked at $1.83M in Q3 2025.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.